A carbon-11 labeled imidazo[1,2-

Wenqing Liu, Wenjie Ma, Min Wang, Zhuangzhuang Wang, Shaun D Grega, Qi-Huang Zheng, Zhidong Xu

Open access · greenAbstract read

In one paragraph

Article in American journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 74% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Wenqing LiuCollege of Chemical & Pharmaceutical Engineering, Key Laboratory of Molecular Chemistry for Medicine of Hebei Province, Hebei University of Science & Technology Shijiazhuang, Hebei, China.

Wenjie MaCollege of Chemical & Pharmaceutical Engineering, Key Laboratory of Molecular Chemistry for Medicine of Hebei Province, Hebei University of Science & Technology Shijiazhuang, Hebei, China.

Min WangDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA.

Zhuangzhuang WangCollege of Chemical & Pharmaceutical Engineering, Key Laboratory of Molecular Chemistry for Medicine of Hebei Province, Hebei University of Science & Technology Shijiazhuang, Hebei, China.

Shaun D GregaDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA.

Qi-Huang ZhengDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine Indianapolis, IN, USA.

Zhidong XuCollege of Chemical & Pharmaceutical Engineering, Key Laboratory of Molecular Chemistry for Medicine of Hebei Province, Hebei University of Science & Technology Shijiazhuang, Hebei, China.

Hebei University of Science and Technology · CNIndiana University – Purdue University Indianapolis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The PI3K/Akt/mTOR pathway is frequently dysregulated in cancer due to its central role in cell growth, survival, and proliferation. Overactivation of the PI3K/Akt/mTOR pathway may occur through varying mechanisms including mutations, gene amplification, and upstream signaling events, ultimately resulting in cancer. Therefore, PI3K/Akt/mTOR pathway has emerged as an attractive target for cancer therapy and imaging. A promising approach to inhibit this pathway involves a simultaneous inhibition of both PI3K and mTOR using a dual inhibitor. Recently, a potent dual PI3K/mTOR inhibitor, 2,4-difluoro-

Indexed as

cancer imagingcarbon-11 labeled PI3K/mTOR dual inhibitormammalian target of rapamycin (mTOR)Phosphoinositide 3-kinase (PI3K)positron emission tomography (PET)radiosynthesis

Identifiers

PMID37457324

PMCPMC10349286

OpenAlexW4384493219

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.